|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 04-27 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/08/25 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 1.68B 52.12M 45.09M 42.1M 38.62M 72.64M 4.96B 73.8M 494M 194M 2.49B 196M 191M 8.22B | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 1.97B 61.07M 52.82M 49.33M 45.25M 85.11M 5.81B 86.46M 579M 227M 2.91B 229M 224M 9.63B | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 199.22 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 11/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 01/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping-Ho Yan
BRD | Director/Board Member | - | - |
Ying Yun Fan
BRD | Director/Board Member | - | 30/06/2020 |
Feng Lin Hsu
BRD | Director/Board Member | 76 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -58.23% | 52.12M | |
| -0.52% | +3.21% | +89.52% | +127.32% | 1,057B | |
| +0.88% | +1.13% | +49.56% | +49.69% | 625B | |
| +0.89% | -1.95% | +24.23% | +64.44% | 435B | |
| +0.71% | +3.87% | +49.07% | +37.85% | 363B | |
| +0.64% | -0.49% | +33.94% | +40.01% | 296B | |
| +0.39% | -5.83% | +8.92% | +7.85% | 249B | |
| +1.51% | +6.69% | +42.58% | +57.57% | 222B | |
| +3.92% | -0.46% | -5.56% | -52.32% | 209B | |
| +1.80% | +2.30% | +11.56% | +66.35% | 165B | |
| Average | +1.20% | +1.22% | +30.38% | +34.05% | 362.08B | |
| Weighted average by Cap. | +0.66% | +1.22% | +48.72% | +64.63% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 539M 16.69M 14.43M 13.48M 12.36M 23.25M 1.59B 23.62M 158M 62.07M 796M 62.66M 61.28M 2.63B | 514M 15.93M 13.78M 12.87M 11.8M 22.2M 1.52B 22.55M 151M 59.26M 760M 59.82M 58.51M 2.51B |
| Net income | -175M -5.4M -4.67M -4.37M -4M -7.53M -514M -7.65M -51.21M -20.1M -258M -20.29M -19.85M -852M | -296M -9.17M -7.94M -7.41M -6.8M -12.79M -873M -12.99M -86.95M -34.13M -438M -34.45M -33.7M -1.45B |
| Net Debt | 246M 7.63M 6.6M 6.16M 5.65M 10.63M 726M 10.8M 72.3M 28.38M 364M 28.65M 28.02M 1.2B | 289M 8.95M 7.74M 7.23M 6.63M 12.47M 851M 12.67M 84.78M 33.28M 427M 33.59M 32.86M 1.41B |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
